tazarotene profile

tazarotene: a topical acetylenic retinoid; a topical kerytolytic [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	5381
CHEMBL ID	1657
CHEBI ID	32184
SCHEMBL ID	3134
MeSH ID	M0230113

Synonym
BIDD:GT0293
AC-755
AB01274801-01
tazoral
suretin
fabior
agn-190168
avage
tazorac
zorac
ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate
agn 190168
c21h21no2s
3-pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2h-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester
ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate
tazarotene
118292-40-3
tazarotenum
tazaroteno
CHEBI:32184 ,
ethyl 6-[(4,4-dimethyl-3,4-dihydro-2h-thiochromen-6-yl)ethynyl]nicotinate
DB00799
avage (tn)
tazorac (tn)
D01132
fabior (tn)
tazarotene (jan/usan/inn)
NCGC00167525-01
FT-0652578
bdbm50265951
idp-123
CHEMBL1657 ,
ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate
dtxcid3026691
cas-118292-40-3
tox21_112522
dtxsid5046691 ,
tazarotene [usan:inn:ban]
unii-81bdr9y8ps
81bdr9y8ps ,
zora
HY-15388
CS-1029
smr002096194
MLS003915630
BCP0726000163
NCGC00167525-03
tazarotene [orange book]
duobrii component tazarotene
tazarotene [mi]
tazarotene [jan]
tazarotene component of duobrii
tazarotene [inn]
tazarotene [who-dd]
tazarotene [usan]
idp-118 component tazarotene
tazarotene [mart.]
arazlo
tazarotene [vandf]
ethyl 6-[(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate
tazarotene [inci]
6-(4,4-dimethyl-thiochroman-6-ylethynyl)-nicotinic acid ethyl ester
S1569
AKOS015902872
gtpl6952
ethyl 6-[2-(4,4-dimethyl-3,4-dihydro-2h-1-benzothiopyran-6-yl)ethynyl]pyridine-3-carboxylate
SCHEMBL3134
tox21_112522_1
NCGC00167525-02
BS-1012
ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)-ethynyl)nicotinate
ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)-ethynyl]nicotinate
ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate
6-(4,4-dimethylthiochroman-6-ylethynyl) nicotinic acid ethyl ester
6-[2-(3,4-dihydro-4,4-dimethyl-2h-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylicacidethylester
T3108
mfcd00867628
ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]pyridine-3-carboxylate
6-[2-(3,4-dihydro-4,4-dimethyl-2h-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester
Q-102516
tox21 112522
ethyl 6-[(4,4-dimethyl-3,4-dihydro-2h-thiochromen-6-yl)ethynyl]pyridine-3-carboxylate
acnitaz
AB01274801_02
sr-01000931253
SR-01000931253-2
HMS3655K05
SW220026-1
ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate;6-(4,4-dimethyl-thiochroman-6-ylethynyl)-nicotinic acid ethyl ester
agn190168, agn-190168
BCP22966
6-[2-(3,4-dihydro-4,4-dimethyl-2h-1-benzothiopyran-6-yl)ethynyl]- 3-pyridinecarboxylic acid ethyl ester
Q3981685
tazarotene (avage)
tazarotene,(s)
AMY31169
HMS3747C19
HMS3747E19
CCG-268046
6-(2-(4,4-dimethyl-thiochroman-6yl)ethynyl)-nicotinic acid ethyl ester
A846572
(+/-)octahydrocyclopenta[b]pyrrole-2-carboxylicacidhydrochloride
SY053169
tazarotene- bio-x
BT164442
d05ax05
tazarotene cream
6-((3,4-dihydro-4,4-dimethyl-2h-1-benzothiopyran-6-yl)ethynyl)-3-pyridinecarboxylic acid, ethyl ester
ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate
tazarotene (mart.)
ethyl 6-((4,4-dimethyl-3,4-dihydro-2h-thiochromen-6-yl)ethynyl)nicotinate
Z1424590960

Excerpt	Reference	Relevance
"Tazarotene 0.045% lotion is an effective and well-tolerated retinoid recently approved by the US Food and Drug Administration (FDA) for treating acne vulgaris in individuals 9 years of age and older."	( Tazarotene 0.045% Lotion: A Novel Retinoid Formulation. Feldman, SR; Mohney, LA; Singh, R, 2022)	3.61
"Tazarotene is a prodrug that belongs to the acetylenic class of retinoids. "	( Insights into the degradation chemistry of tazarotene, a third generation acetylenic retinoid: LC-HRMS (Orbitrap), LC-MS Balhara, A; Giri, S; Sahu, A; Singh, DK; Singh, S, 2020)	2.26
"Tazarotene is a synthetic retinoid, with immunomodulating properties and anti-inflammatory activity."	( Comparative study between the effect of topical tazarotene 0.1 gel alone vs its combination with tioconazole nail paint in treatment of onychomycosis. El-Salam, SSA; Mahmoud, MT; Omar, GA; Said, M, 2020)	1.54
"Tazarotene is a recently discovered small molecule drug and functions to promote neovascularization and tissue repair."	( Tazarotene-loaded PLGA nanoparticles potentiate deep tissue pressure injury healing via VEGF-Notch signaling. Guo, J; Han, J; Liu, P; Si, R; Wang, A; Yang, X; Zhang, J; Zhang, Z; Zhao, M, 2020)	2.72
"Tazarotene (TAZ) is a topical synthetic retinoid used in psoriasis treatment, however, it is extremely lipophilic and exhibits skin irritation. "	( Novel antipsoriatic fluidized spanlastic nanovesicles: In vitro physicochemical characterization, ex vivo cutaneous retention and exploratory clinical therapeutic efficacy. El-Gogary, RI; Elmowafy, E; Nasr, M; Ragai, MH, 2019)	1.96
"Tazarotene foam, 0.1 % is an alternative to gel with less systemic exposure."	( Tazarotene foam versus tazarotene gel: a randomized relative bioavailability study in acne vulgaris. Alió Saenz, AB; Jarratt, M; Werner, CP, 2013)	3.28
"Tazarotene is a synthetic retinoid that, depending on the concentration and vehicle, is approved by the US Food and Drug Administration for the topical treatment of acne vulgaris (AV) and plaque psoriasis. "	( A status report on topical tazarotene in the management of acne vulgaris. Del Rosso, JQ; Tanghetti, E, 2013)	2.13
"Tazarotene is a topically-applied, receptor-selective retinoid that has been shown to modulate several major pathogenic factors of psoriasis. "	( Periungual pyogenic granulomas due to topical tazarotene for nail psoriasis. Patrizi, A; Piraccini, BM; Venturi, M, 2014)	2.1
"Tazarotene is a topical retinoid available as a cream, gel and foam. "	( Tazarotene foam, 0.1%, for the treatment of acne. Feldman, SR; Hill, D; Narahari, S; Smith, JA, 2016)	3.32
"Tazarotene is a new 3rd generation topical acetylenic retinoid. "	( Topical tazarotene cream (0.1%) in the treatment of facial acne: an open clinical trial. Choudhury, AM; Islam, MT; Paul, HK; Rahman, MA; Zakaria, AS, 2010)	2.24
"Tazarotene is a receptor-selective retinoid, which is efficacious in the treatment of patients with psoriasis, acne vulgaris, and photoaging. "	( Optimizing treatment with topical tazarotene. Guenther, LC, 2003)	2.04
"Tazarotene is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors RARbeta and RARgamma. "	( A phase 1 study of tazarotene in adults with advanced cancer. Burnett, RD; Fainaru, I; Ganesan, TS; Harris, AL; Jones, PH; Nadolny, P; Rustin, GJ; Talbot, DC; Tang-Liu, D; Walker, P; Yu, Z, 2003)	2.09
"Tazarotene is a retinoic acid receptor selective retinoid that upregulates a tumor suppressor, tazarotene-induced gene 3 (TIG-3), in keratinocytes and psoriasis."	( Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. Duvic, M; Hazarika, P; Herne, K; Joseph, A; Ni, X; Schulz, C; Sui, D; Talpur, R; Ward, S, 2003)	2.48
"Tazarotene is a member of the new generation of receptor-selective, synthetic retinoids for the topical treatment of mild to moderate plaque psoriasis, acne vulgaris and photoaging. "	( Tazarotene: therapeutic strategies in the treatment of psoriasis, acne and photoaging. Korting, HC; Roeder, A; Schäfer-Korting, M; Schaller, M, )	3.02
"Tazarotene is an alternative for vitamin D(3) treatment if this treatment fails."	( Established treatments of psoriasis. van de Kerkhof, PC; Vissers, WH, 2004)	1.04
"Tazarotene is a prodrug selective for RARbeta/gamma, thereby motivating interest in determining whether tazarotene might activate putative tumor suppressor activity."	( A retinoic acid receptor beta/gamma-selective prodrug (tazarotene) plus a retinoid X receptor ligand induces extracellular signal-regulated kinase activation, retinoblastoma hypophosphorylation, G0 arrest, and cell differentiation. Chandraratna, R; Fenning, R; Varvayanis, S; Walker, P; Yen, A, 2004)	1.29
"Tazarotene is a prodrug metabolized to tazarotenic acid that modulates cellular differentiation, desquamation, and inflammation."	( Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids. Bikowski, JB, )	0.85
"Tazarotene (Tazorac) is a topical retinoid indicated for the treatment of plaque psoriasis. "	( Topical tazarotene: a review of its use in the treatment of plaque psoriasis. Dando, TM; Wellington, K, 2005)	2.21
"Tazarotene is a topically applied retinoid that targets the skin, the site of the fundamental defect(s) in psoriasis, modulating the major causes of the disease and achieving sustained efficacy. "	( Tazarotene--first of a new generation of receptor-selective retinoids. Chandraratna, RA, 1996)	3.18
"Tazarotene is a new topical retinoid which has proven to be efficacious in the treatment of mild-to-moderate plaque psoriasis."	( Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis. Weinstein, GD, 1996)	1.26
"Tazarotene is a novel acetylenic retinoid for the treatment of psoriasis and acne. "	( Metabolic deesterification of tazarotene in human blood and rat and human liver microsomes. Baumgarten, V; Duff, S; Madhu, C; Rix, P; Small, D; Tang-Liu, D, 1997)	2.03
"Tazarotene is a retinoic acid receptor-specific retinoid with demonstrated efficacy in the topical treatment of psoriasis."	( Molecular mechanisms of tazarotene action in psoriasis. Asano, AT; Chandraratna, RA; Duvic, M; Nagpal, S, 1997)	1.33
"Tazarotene is a novel acetylenic retinoid undergoing clinical trials for the topical treatment of mild-to-moderate plaque psoriasis."	( Clinical safety of tazarotene in the treatment of plaque psoriasis. Marks, R, 1997)	1.35
"Tazarotene appears to be an effective addition to the currently available treatments for plaque psoriasis."	( Tazarotene gel: efficacy and safety in plaque psoriasis. Weinstein, GD, 1997)	2.46
"Tazarotene (Tazorac) is a new vitamin A derivative and the first topical retinoid to demonstrate therapeutic success in treating plaque-type psoriasis."	( New treatment options for psoriasis. McClelland, PB, 1997)	1.02
"Tazarotene is a topical retinoid that appears to exert its effects via retinoic acid receptors. "	( Tazarotene. Benfield, P; Brogden, RN; Foster, RH, 1998)	3.19
"Tazarotene is a retinoid with properties that are a result of this rational approach to drug discovery."	( Current research and future developments in retinoids: oral and topical agents. Chandraratna, RA, 1998)	1.02
"Tazarotene is a synthetic retinoid that is used in the clinic for the treatment of psoriasis."	( Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. Chandraratna, RA; Deucher, A; DiSepio, D; Duvic, M; Eckert, RL; Ghosn, C; Nagpal, S; Robinson, N, 1998)	1.02
"Tazarotene (AGN 190168) is a new acetylenic retinoid which is effective for the topical treatment of patients with stable plaque psoriasis and mild to moderate acne vulgaris. "	( Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Matsumoto, RM; Tang-Liu, DD; Usansky, JI, 1999)	2
"Tazarotene is an important addition to the therapeutic possibilities in Darier disease."	( [Follicular dyskeratosis: successful treatment with local retinoid]. Altmeyer, P; Oster-Schmidt, C; Stücker, M, 2000)	1.03
"Tazarotene is a pro-drug of tazarotenic acid, a receptor-selective retinoid, which has shown efficacy in the treatment of these disorders."	( Topical tazarotene therapy for psoriasis, acne vulgaris, and photoaging. Guenther, LC, 2002)	1.47

Excerpt	Reference	Relevance
"Tazarotene has a rapid onset of action indicated by significant improvements as early as the first week of treatment."	( Tazarotene gel: efficacy and safety in plaque psoriasis. Weinstein, GD, 1997)	2.46
"Tazarotene has also been shown to be effective in psoriasis, with efficacy maintained several weeks posttreatment."	( Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy , 2019)	1.57
"Tazarotene has also been shown to be effective in psoriasis, with efficacy maintained several weeks posttreatment."	( Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy. Green, LJ; Lin, T; Pariser, DM; Pillai, R; Stein Gold, L; Sugarman, JL, 2018)	1.54
"Tazarotene 0.1% gel has comparable clinical efficacy to CCT 5% ointment. "	( Topical tazarotene vs. coal tar in stable plaque psoriasis. De, D; Dogra, S; Kaur, I; Kumar, B; Kumar, U, 2010)	2.24
"Tazarotene has been shown to upregulate the tumor suppressor, tazarotene induced gene 3, which is overexpressed in psoriasis and skin cancer."	( Efficacy and safety of topical tazarotene: a review. Cox, K; Duvic, M; Talpur, R, 2009)	1.36
"Tazarotene has been proposed for the treatment of BCC; however, data on its efficacy are lacking."	( Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Angeloni, C; Bianchi, L; Campione, E; Chimenti, S; Costanzo, A; Orlandi, A; Spagnoli, LG, 2004)	1.3
"Tazarotene has low systemic absorption after topical administration."	( Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. Chandraratna, RA, 1997)	2.46
"Tazarotene has a rapid onset of action indicated by significant improvements as early as the first week of treatment."	( Tazarotene gel: efficacy and safety in plaque psoriasis. Weinstein, GD, 1997)	2.46
"Tazarotene has been demonstrated to be significantly more effective than vehicle, and comparable in efficacy to fluocinonide 0.05%, but with a more sustained therapeutic effect after treatment is stopped."	( Clinical efficacy and safety of tazarotene: optimizing clinical results. Lebwohl, M, 1998)	1.31
"Tazarotene has been shown to be efficacious in plaque-type psoriasis."	( Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. Behrens, S; Grundmann-Kollmann, M; Kerscher, M; Peter, RU; Schiener, R, 2000)	1.25

Excerpt	Reference	Relevance
"Tazarotene may inhibit abnormal proliferation of keratinocytes through down-regulating PML gene expression in active psoriatic epidermis."	( [Inhibition of promyelocytic leukemia gene by tazarotene in hyperproliferative epidermis of psoriasis]. Liu, P; Peng, ZH; Tan, SS; Wang, QY; Yan, HL, 2006)	2.03
"Tazarotene promotes healing of psoriatic lesions by modulating the key pathogenetic factors in this disease."	( Early clinical development of tazarotene. Marks, R, 1996)	1.3

Excerpt	Reference	Relevance
"Tazarotene treatment was associated with increased TIG-3 protein and mRNA expression in basal cell carcinomas compared to baseline levels (p < or = 0.001 and p = 0.028, respectively)."	( Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. Duvic, M; Hazarika, P; Herne, K; Joseph, A; Ni, X; Schulz, C; Sui, D; Talpur, R; Ward, S, 2003)	2.48
"Tazarotene treatment was associated with significant irritation, causing its discontinuation in one third of patients."	( Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. Agero, AL; Dusza, SW; Halpern, AC; Kemeny, NE; Lieb, JA; Myskowski, PL; Saltz, L; Scope, A, 2007)	1.29
"Tazarotene effectively treats mild-to-moderate plaque-type psoriasis, the benefits seem to be sustained after the cessation of therapy, and once-daily treatment is equally effective as more frequent application."	( Early clinical development of tazarotene. Marks, R, 1996)	1.3
"The tazarotene-UVB treatment was well tolerated, and no phototoxicity was observed."	( Tazarotene in combination with phototherapy. Koo, JY, 1998)	2.22
"Tazarotene treatment increases TIG3 expression in primary human keratinocytes and in vivo in psoriatic lesions."	( Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. Chandraratna, RA; Deucher, A; DiSepio, D; Duvic, M; Eckert, RL; Ghosn, C; Nagpal, S; Robinson, N, 1998)	1.02
"The tazarotene treatment resulted in a significantly greater reduction in onycholysis in occluded nails (P < or = .05 at weeks 4 and 12) and a significantly greater reduction in onycholysis in nonoccluded nails (P < or = .05 at week 24)."	( Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Scher, RK; Stiller, M; Zhu, YI, 2001)	2.23
"Tazarotene treatment was associated with a significantly greater incidence of treatment success (defined as > or = 50% global improvement [67% vs 49%; P=.03]) and significantly greater reductions in overall disease severity (36% vs 26%; P=.02) and noninflammatory lesion count (60% vs 38% at week 12; P=.02) than tretinoin microsponge treatment."	( Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Berson, D; Lee, J; Leyden, JJ; Miller, B; Tanghetti, EA; Ung, M, 2002)	1.43
"Treatment with tazarotene lotion 0.045% was well-tolerated, with erythema, dryness, peeling, oiliness, pruritis, and burning generally rated as trace or mild."	( Efficacy and Safety of Tazarotene Lotion, 0.045% in the Treatment of Truncal Acne Vulgaris. Kircik, L, 2022)	1.37
"Treatment with tazarotene resulted in uniform reduction of plaque elevation and was not associated with the development of hot spots."	( Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: a double-blind, randomized, right-left comparison study. Angelo, JS; Kar, BR; Thomas, J, )	0.73
"Treatment with tazarotene offers an opportunity to reduce the cost of care for patients with mild-to-moderate psoriasis and enhance patient satisfaction by gaining more disease-free days."	( A pharmacoeconomic analysis of topical therapies for patients with mild-to-moderate stable plaque psoriasis: a US study. An, P; LaPensee, K; Marchetti, A, )	0.47
"Pretreatment with tazarotene 0.1% gel 3 times per week for 2 weeks before phototherapy significantly reduced the mean minimal erythema dose (MED) for UVB from 56.25 to 42.50 mJ/cm(2) (P <.01), and significantly reduced the mean UVA exposure required to induce immediate pigment darkening from 20.18 to 18.50 J/cm(2) (P <.05)."	( Interactions between tazarotene and ultraviolet light. Hecker, D; Kuroda, K; Lebwohl, M; Worsley, J; Yueh, G, 1999)	0.95

Excerpt	Reference	Relevance
" Disadvantages of currently available therapies include lack of short-term efficacy and long-term maintenance, adverse effects, and cosmetic problems."	( Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis. Weinstein, GD, 1996)	0.54
"Once-daily tazarotene was effective and safe as a topical monotherapy for plaque psoriasis, providing rapid reduction of signs and symptoms."	( Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. Chandraratna, RA; Duvic, M; Friedman, DJ; Gibson, JR; Jegasothy, BV; Jorizzo, JL; Krueger, GG; Lew-Kaya, DA; Lowe, NJ; Lue, JC; Sefton, J; Shmunes, E; Tschen, EH; Weinstein, GD, 1997)	2.13
" Tazarotene is generally well tolerated, with adverse events limited to local irritation."	( Tazarotene gel: efficacy and safety in plaque psoriasis. Weinstein, GD, 1997)	2.65
" Treatment-related adverse effects were generally limited to mild or moderate local irritation and were less frequent with the treatment regimen administered once daily."	( The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Chandraratna, RA; Drake, LA; Elias, PM; Guzzo, C; Krueger, GG; Lew-Kaya, DA; Lowe, NJ; Lue, JC; Sefton, J; Weinstein, GD, 1998)	0.6
" Its adverse effects consist primarily of mild to moderate local irritation with no reports of treatment-related systemic adverse effects."	( Clinical efficacy and safety of tazarotene: optimizing clinical results. Lebwohl, M, 1998)	0.58
" Limited systemic exposure to the drug also ensures that any adverse effects are local effects rather than systemic effects."	( Pharmacokinetics and safety of tazarotene. Menter, A, 2000)	0.59
"In the treatment of plaque psoriasis with corticosteroids, long-term efficacy and safety are often compromised by tachyphylaxis, steroid rebound, and adverse effects."	( Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. Lebwohl, M, 2000)	0.52
" Our purpose is to compare the rates of adverse events associated with different topical psoriasis treatments."	( A systematic review of adverse effects associated with topical treatments for psoriasis. Bruner, CR; Feldman, SR; Fleischer, AB; Ventrapragada, M, 2003)	0.32
" Common adverse events included signs and symptoms of skin irritation."	( Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. Gibson, JR; Koo, JY; Krueger, GG; Lebwohl, MG; Lew-Kaya, DA; Lowe, NJ; Menter, MA; Sefton, J; Walker, PS; Weinstein, GD, 2003)	1.76
"Tazarotene creams were associated with significant reductions in the severity of the clinical signs of psoriasis and were found to be safe with acceptable tolerability."	( Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. Gibson, JR; Koo, JY; Krueger, GG; Lebwohl, MG; Lew-Kaya, DA; Lowe, NJ; Menter, MA; Sefton, J; Walker, PS; Weinstein, GD, 2003)	3.2
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" Local adverse effects, including erythema, dryness, itching, and stinging, occur frequently during the early treatment phase."	( Topical retinoids in acne vulgaris: update on efficacy and safety. Gollnick, H; Thielitz, A, 2008)	0.35
" Adverse effects are limited to mild to moderate local irritation and erythema as seen with the 'retinization period' of other topical retinoid therapies."	( Efficacy and safety of topical tazarotene: a review. Cox, K; Duvic, M; Talpur, R, 2009)	0.64
" Safety and treatment emergent adverse events (TEAEs) were evaluated throughout."	( A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis. Alexander, BJ; Gold, LS; Lebwohl, MG; Pariser, DM; Pillai, R; Sugarman, JL, 2017)	0.66
" Safety and treatment-emergent adverse events were evaluated throughout."	( Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. Gold, LS; Israel, R; Lebwohl, MG; Lin, T; Martin, G; Pariser, DM; Pillai, R; Ramakrishna, T; Sugarman, JL, 2018)	0.72
" The most frequently reported treatment-related adverse events were contact dermatitis (6."	( Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. Gold, LS; Israel, R; Lebwohl, MG; Lin, T; Martin, G; Pariser, DM; Pillai, R; Ramakrishna, T; Sugarman, JL, 2018)	0.72
" The most common side effect is mild-to-moderate local irritation, which limited its role as a single agent for psoriasis."	( Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy Lebwohl, M; Stein Gold, L; Tanghetti, E, 2018)	1.92
" Safety and treatment emergent adverse events (TEAEs) were evaluated throughout."	( Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials Israel, R; Lebwohl, MG; Lin, T; Stein Gold, L; Sugarman, JL, 2019)	0.76
" The most common treatment-related adverse events were application site reactions of dermatitis, pruritus, pain and irritation."	( Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. Han, G; Harris, S; Jacobson, A; Lebwohl, MG; Lin, T; Papp, K; Pariser, DM; Stein Gold, L, 2021)	0.85
" Quality of life, treatment-emergent adverse events (TEAEs), and cutaneous safety/tolerability were also assessed."	( Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne. Callender, V; Cook-Bolden, F; Del Rosso, J; Draelos, Z; Guenin, E; Stein Gold, L; Tyring, S; Werschler, W; Zeichner, J, 2022)	1.03

Excerpt	Reference	Relevance
"The pharmacokinetic profile of tazarotene helps to ensure that systemic exposure to the drug and its metabolites is minimal."	( Pharmacokinetics and safety of tazarotene. Menter, A, 2000)	0.88
"Two separate, randomised, single-centre, nonblinded, parallel-group pharmacokinetic studies were conducted."	( Pharmacokinetics of tazarotene cream 0.1% after a single dose and after repeat topical applications at clinical or exaggerated application rates in patients with acne vulgaris or photodamaged skin. Lew-Kaya, D; Sefton, J; Tang-Liu, DD; Walker, P; Yu, D; Yu, Z, 2003)	0.64
"Two separate open-label, parallel-group, single-centre, pharmacokinetic and pharmacodynamic interaction studies."	( Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive. Tang-Liu, DD; Walker, PS; Yu, D; Yu, Z, 2004)	1.77
" Pharmacokinetic parameters of plasma norethindrone and ethinylestradiol were compared before and after tazarotene administration (cycle day 6 of the second and third cycles, respectively)."	( Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive. Tang-Liu, DD; Walker, PS; Yu, D; Yu, Z, 2004)	1.98
"1 mg), the area under the plasma concentration-time curve from zero to 24 hours (AUC24) and the peak concentration in plasma (Cmax) for tazarotenic acid were 121 +/- 27 microg."	( Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive. Tang-Liu, DD; Walker, PS; Yu, D; Yu, Z, 2004)	1.77

Excerpt	Reference	Relevance
"The use of a topical corticosteroid in combination with tazarotene has theoretic appeal because each drug has a different mechanism of action, and it is therefore likely that combination therapy will offer additive or synergistic effects."	( Tazarotene in combination with topical corticosteroids. Lebwohl, M; Poulin, Y, 1998)	1.99
"1% gel once daily, followed by tazarotene plus UVB therapy (tazarotene-UVB) 3 times per week for 10 weeks, was more effective than UVB therapy alone or in combination with vehicle gel in reducing plaque elevation, scaling, and erythema."	( Tazarotene in combination with phototherapy. Koo, JY, 1998)	2.03
"05% monotherapy, and were higher still when tazarotene was used in combination with mometasone furoate."	( Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. Poulin, YP, 1999)	2.01
"Phototherapy is often used in combination with other antipsoriatic treatments in an attempt to improve efficacy and reduce patients' cumulative exposure to radiation."	( Optimizing therapy: tazarotene in combination with phototherapy. Lowe, NJ, 1999)	0.63
" When valproic acid is combined with tazarotene or isotretinoin, it does not change their photocarcinogenicity significantly."	( Photocarcinogenesis of topical tazarotene and isotretinoin alone and in combination with valproic acid in hairless mice. Lerche, CM; Philipsen, PA; Sehested, M; Wulf, HC, 2008)	0.9
" The results suggest that anti-inflammatory agents such as dapsone can effectively treat early stages of acne (both comedonal and noncomedonal) when used in combination with a retinoid."	( Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris. Dhawan, S; Downie, J; Draelos, Z; Germain, MA; Green, L; Kasteler, JS; Kircik, L; Ling, M; Oefelein, MG; Tanghetti, E, 2011)	0.57
" The present study was designed to investigate drug-drug interaction in a new combination cream which contains both tazarotene (TZRT) and betamethasone dipropionate (BTMSDP) by comparing the pharmacokinetic (PK) behaviors of TZRT, BTMSDP, and their major metabolites, tazarotenic acid (TZRTAC) and betamethasone (BTMS) with those in the commonly prescribed TZRT gel and BTMSDP cream."	( Evaluation of change in the skin concentration of tazarotene and betamethasone dipropionate based on drug-drug interaction for transdermal drug delivery in miniature pig. Chen, D; Ma, P; Yang, J; Yu, B; Yuan, L, 2015)	0.88
"1% gel alone in comparison with its combination with tioconazole nail paint in the treatment of onychomycosis."	( Comparative study between the effect of topical tazarotene 0.1 gel alone vs its combination with tioconazole nail paint in treatment of onychomycosis. El-Salam, SSA; Mahmoud, MT; Omar, GA; Said, M, 2020)	0.81

Excerpt	Reference	Relevance
" The systemic bioavailability of tazarotene (measured as tazarotenic acid) is low, approximately 1% after single and multiple topical applications to healthy skin."	( Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Matsumoto, RM; Tang-Liu, DD; Usansky, JI, 1999)	0.84
" Topical administration of acitretin may lessen the risk of systemic toxicity while increasing local bioavailability in the skin."	( Effects of topically applied acitretin in reconstructed human epidermis and the rhino mouse. Chern, WH; Hofland, HE; Houlden, RJ; Hsia, E; Johnston, MJ, 2008)	0.35
" This single-centre, randomized, open-label study assessed relative bioavailability of its active metabolite tazarotenic acid after dosing of tazarotene foam or gel."	( Tazarotene foam versus tazarotene gel: a randomized relative bioavailability study in acne vulgaris. Alió Saenz, AB; Jarratt, M; Werner, CP, 2013)	2.03
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" This study used poly (lactic-co-glycolic acid) (PLGA) as nanoparticle carriers loaded with tazarotene (Ta/PLGA NPs) for drug delivery and to overcome shortcomings associated with the low water solubility, short half-life, easy photolysis and low bioavailability of tazarotene itself."	( Tazarotene-loaded PLGA nanoparticles potentiate deep tissue pressure injury healing via VEGF-Notch signaling. Guo, J; Han, J; Liu, P; Si, R; Wang, A; Yang, X; Zhang, J; Zhang, Z; Zhao, M, 2020)	2.22

Excerpt	Relevance	Reference
" Finally, a dose-response study showed that the de novo appearance of K4 can be utilized as a sensitive test for retinoid bioactivity in epidermis in vivo."	( Keratin 4 upregulation by retinoic acid in vivo: a sensitive marker for retinoid bioactivity in human epidermis. Törmä, H; Vahlquist, A; Virtanen, M, 2000)	0.31
" Plasma concentrations of tazarotenic acid were found to peak rapidly within 1-3 h of dosing and thereafter declined quickly."	( A phase 1 study of tazarotene in adults with advanced cancer. Burnett, RD; Fainaru, I; Ganesan, TS; Harris, AL; Jones, PH; Nadolny, P; Rustin, GJ; Talbot, DC; Tang-Liu, D; Walker, P; Yu, Z, 2003)	0.65
" Dose-response studies showed that diminishing tazarotene progressively diminished both induced cell differentiation and G0 arrest, where the doses for cellular effects were consistent with the transcriptional transactivation data."	( A retinoic acid receptor beta/gamma-selective prodrug (tazarotene) plus a retinoid X receptor ligand induces extracellular signal-regulated kinase activation, retinoblastoma hypophosphorylation, G0 arrest, and cell differentiation. Chandraratna, R; Fenning, R; Varvayanis, S; Walker, P; Yen, A, 2004)	0.83
" A dose-response relationship was evident for both effectiveness and skin irritation."	( Interventions for photodamaged skin. Brooke, RC; Griffiths, CE; Hollis, S; Samuel, M, 2005)	0.33
" This single-centre, randomized, open-label study assessed relative bioavailability of its active metabolite tazarotenic acid after dosing of tazarotene foam or gel."	( Tazarotene foam versus tazarotene gel: a randomized relative bioavailability study in acne vulgaris. Alió Saenz, AB; Jarratt, M; Werner, CP, 2013)	2.03
" Accumulation was observed upon repeated dosing with steady-state conditions achieved at day 20."	( Tazarotene foam versus tazarotene gel: a randomized relative bioavailability study in acne vulgaris. Alió Saenz, AB; Jarratt, M; Werner, CP, 2013)	1.83
" Moreover, the TZR is required alternative methods for routine quality control and to estimate TZR in pharmaceutical dosage form especially in pharmacokinetic studies of topical preparation."	( Review on Characteristics and Analytical Methods of Tazarotene: An Update. Gaikwad, J; Hatware, KV; Sharma, S, 2020)	0.81
" No method has been reported so far for the simultaneous estimation of BV and TZ in topical dosage forms."	( UV spectrophotometric method for simultaneous estimation of betamethasone valerate and tazarotene with absorption factor method: Application for in-vitro and ex-vivo characterization of lipidic nanocarriers for topical delivery. Dubey, SK; Gorantla, S; Mahmood, A; Rapalli, VK; Saha, RN; Singhvi, G; Waghule, T, 2020)	0.78

Role	Description
keratolytic drug	A drug that softens, separates, and causes desquamation of the cornified epithelium or horny layer of skin. Keratolytic drugs are used to expose mycelia of infecting fungi or to treat corns, warts, and certain other skin diseases.
prodrug	A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
teratogenic agent	A role played by a chemical compound in biological systems with adverse consequences in embryo developments, leading to birth defects, embryo death or altered development, growth retardation and functional defect.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
retinoid	Oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.
thiochromane	Any organic heterobicyclic compound consisting of a benzene ring fused to a thiopyran.
pyridines	Any organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
acetylenic compound	Any organic molecule containing a C#C bond.
ethyl ester	Any carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
acetylcholinesterase	Homo sapiens (human)	Potency	3.8902	0.0025	41.7960	15,848.9004	AID1347398
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	0.7498	0.0060	38.0041	19,952.5996	AID1159521
SMAD family member 2	Homo sapiens (human)	Potency	24.4901	0.1737	34.3047	61.8120	AID1346859; AID1347035
USP1 protein, partial	Homo sapiens (human)	Potency	22.3872	0.0316	37.5844	354.8130	AID504865
SMAD family member 3	Homo sapiens (human)	Potency	24.4901	0.1737	34.3047	61.8120	AID1346859; AID1347035
TDP1 protein	Homo sapiens (human)	Potency	5.4640	0.0008	11.3822	44.6684	AID686978; AID686979
AR protein	Homo sapiens (human)	Potency	31.2718	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID743036
progesterone receptor	Homo sapiens (human)	Potency	26.6032	0.0004	17.9460	75.1148	AID1346784
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	10.9640	0.0123	7.9835	43.2770	AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	0.0148	0.0013	10.1577	42.8575	AID1259256
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	3.6874	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	0.2617	0.0008	17.5051	59.3239	AID1159527; AID1159531
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	22.8506	0.0015	30.6073	15,848.9004	AID1224848; AID1224849; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	25.4403	0.3758	27.4851	61.6524	AID743217; AID743220; AID743239
pregnane X nuclear receptor	Homo sapiens (human)	Potency	33.4915	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	9.9912	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743080; AID743091
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	29.8470	0.0010	24.5048	61.6448	AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	20.0629	0.0010	19.4141	70.9645	AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	11.8823	0.0237	23.2282	63.5986	AID743222
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	3.1623	0.0355	20.9770	89.1251	AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	0.0473	0.0017	23.8393	78.1014	AID743083
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	26.6032	0.0016	28.0151	77.1139	AID1224843; AID1224895
nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus (Norway rat)	Potency	10.0000	0.1000	9.1916	31.6228	AID1346983
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	49.1940	0.0391	47.5451	146.8240	AID1224845
potassium voltage-gated channel subfamily H member 2 isoform d	Homo sapiens (human)	Potency	8.9125	0.0178	9.6374	44.6684	AID588834
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	0.0919	0.0003	23.4451	159.6830	AID743065; AID743067
histone-lysine N-methyltransferase 2A isoform 2 precursor	Homo sapiens (human)	Potency	35.4813	0.0103	23.8567	63.0957	AID2662
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	26.6011	0.0006	27.2152	1,122.0200	AID743202; AID743219
geminin	Homo sapiens (human)	Potency	33.4983	0.0046	11.3741	33.4983	AID624296; AID624297
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	2.8198	0.0056	12.3677	36.1254	AID624032; AID624044
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	0.0298	0.0015	57.7890	15,848.9004	AID1259244
Cellular tumor antigen p53	Homo sapiens (human)	Potency	29.8493	0.0023	19.5956	74.0614	AID651631; AID720552
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	0.0298	0.0015	51.7393	15,848.9004	AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Retinoic acid receptor alpha	Homo sapiens (human)	EC50 (µMol)	0.0630	0.0002	0.1790	2.5119	AID396775
Retinoic acid receptor beta	Homo sapiens (human)	EC50 (µMol)	0.0008	0.0003	0.2311	6.9000	AID396777
Retinoic acid receptor gamma	Homo sapiens (human)	EC50 (µMol)	0.0400	0.0002	0.0613	0.6480	AID392142
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
ureteric bud development	Retinoic acid receptor alpha	Homo sapiens (human)
neural tube closure	Retinoic acid receptor alpha	Homo sapiens (human)
liver development	Retinoic acid receptor alpha	Homo sapiens (human)
glandular epithelial cell development	Retinoic acid receptor alpha	Homo sapiens (human)
growth plate cartilage development	Retinoic acid receptor alpha	Homo sapiens (human)
protein phosphorylation	Retinoic acid receptor alpha	Homo sapiens (human)
germ cell development	Retinoic acid receptor alpha	Homo sapiens (human)
female pregnancy	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of cell population proliferation	Retinoic acid receptor alpha	Homo sapiens (human)
negative regulation of cell population proliferation	Retinoic acid receptor alpha	Homo sapiens (human)
negative regulation of translation	Retinoic acid receptor alpha	Homo sapiens (human)
hippocampus development	Retinoic acid receptor alpha	Homo sapiens (human)
prostate gland development	Retinoic acid receptor alpha	Homo sapiens (human)
negative regulation of granulocyte differentiation	Retinoic acid receptor alpha	Homo sapiens (human)
embryonic camera-type eye development	Retinoic acid receptor alpha	Homo sapiens (human)
regulation of myelination	Retinoic acid receptor alpha	Homo sapiens (human)
response to estradiol	Retinoic acid receptor alpha	Homo sapiens (human)
response to retinoic acid	Retinoic acid receptor alpha	Homo sapiens (human)
negative regulation of type II interferon production	Retinoic acid receptor alpha	Homo sapiens (human)
negative regulation of tumor necrosis factor production	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of interleukin-13 production	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of interleukin-4 production	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of interleukin-5 production	Retinoic acid receptor alpha	Homo sapiens (human)
response to vitamin A	Retinoic acid receptor alpha	Homo sapiens (human)
response to cytokine	Retinoic acid receptor alpha	Homo sapiens (human)
multicellular organism growth	Retinoic acid receptor alpha	Homo sapiens (human)
mRNA transcription by RNA polymerase II	Retinoic acid receptor alpha	Homo sapiens (human)
regulation of apoptotic process	Retinoic acid receptor alpha	Homo sapiens (human)
apoptotic cell clearance	Retinoic acid receptor alpha	Homo sapiens (human)
response to ethanol	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of T-helper 2 cell differentiation	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of neuron differentiation	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of cell cycle	Retinoic acid receptor alpha	Homo sapiens (human)
negative regulation of DNA-templated transcription	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of DNA-templated transcription	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Retinoic acid receptor alpha	Homo sapiens (human)
regulation of synaptic plasticity	Retinoic acid receptor alpha	Homo sapiens (human)
retinoic acid receptor signaling pathway	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of binding	Retinoic acid receptor alpha	Homo sapiens (human)
ventricular cardiac muscle cell differentiation	Retinoic acid receptor alpha	Homo sapiens (human)
Sertoli cell fate commitment	Retinoic acid receptor alpha	Homo sapiens (human)
limb development	Retinoic acid receptor alpha	Homo sapiens (human)
face development	Retinoic acid receptor alpha	Homo sapiens (human)
trachea cartilage development	Retinoic acid receptor alpha	Homo sapiens (human)
chondroblast differentiation	Retinoic acid receptor alpha	Homo sapiens (human)
negative regulation of cartilage development	Retinoic acid receptor alpha	Homo sapiens (human)
cellular response to lipopolysaccharide	Retinoic acid receptor alpha	Homo sapiens (human)
cellular response to retinoic acid	Retinoic acid receptor alpha	Homo sapiens (human)
cellular response to estrogen stimulus	Retinoic acid receptor alpha	Homo sapiens (human)
regulation of hematopoietic progenitor cell differentiation	Retinoic acid receptor alpha	Homo sapiens (human)
negative regulation of miRNA transcription	Retinoic acid receptor alpha	Homo sapiens (human)
cell differentiation	Retinoic acid receptor alpha	Homo sapiens (human)
hormone-mediated signaling pathway	Retinoic acid receptor alpha	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Retinoic acid receptor alpha	Homo sapiens (human)
ureteric bud development	Retinoic acid receptor beta	Homo sapiens (human)
glandular epithelial cell development	Retinoic acid receptor beta	Homo sapiens (human)
growth plate cartilage development	Retinoic acid receptor beta	Homo sapiens (human)
apoptotic process	Retinoic acid receptor beta	Homo sapiens (human)
signal transduction	Retinoic acid receptor beta	Homo sapiens (human)
striatum development	Retinoic acid receptor beta	Homo sapiens (human)
neurogenesis	Retinoic acid receptor beta	Homo sapiens (human)
regulation of myelination	Retinoic acid receptor beta	Homo sapiens (human)
negative regulation of chondrocyte differentiation	Retinoic acid receptor beta	Homo sapiens (human)
embryonic hindlimb morphogenesis	Retinoic acid receptor beta	Homo sapiens (human)
multicellular organism growth	Retinoic acid receptor beta	Homo sapiens (human)
positive regulation of apoptotic process	Retinoic acid receptor beta	Homo sapiens (human)
embryonic eye morphogenesis	Retinoic acid receptor beta	Homo sapiens (human)
embryonic digestive tract development	Retinoic acid receptor beta	Homo sapiens (human)
ventricular cardiac muscle cell differentiation	Retinoic acid receptor beta	Homo sapiens (human)
neural precursor cell proliferation	Retinoic acid receptor beta	Homo sapiens (human)
stem cell proliferation	Retinoic acid receptor beta	Homo sapiens (human)
negative regulation of stem cell proliferation	Retinoic acid receptor beta	Homo sapiens (human)
retinoic acid receptor signaling pathway	Retinoic acid receptor beta	Homo sapiens (human)
hormone-mediated signaling pathway	Retinoic acid receptor beta	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Retinoic acid receptor beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Retinoic acid receptor beta	Homo sapiens (human)
cell differentiation	Retinoic acid receptor beta	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Retinoic acid receptor gamma	Homo sapiens (human)
neural tube closure	Retinoic acid receptor gamma	Homo sapiens (human)
glandular epithelial cell development	Retinoic acid receptor gamma	Homo sapiens (human)
growth plate cartilage chondrocyte growth	Retinoic acid receptor gamma	Homo sapiens (human)
apoptotic process	Retinoic acid receptor gamma	Homo sapiens (human)
positive regulation of cell population proliferation	Retinoic acid receptor gamma	Homo sapiens (human)
negative regulation of cell population proliferation	Retinoic acid receptor gamma	Homo sapiens (human)
regulation of cell size	Retinoic acid receptor gamma	Homo sapiens (human)
anterior/posterior pattern specification	Retinoic acid receptor gamma	Homo sapiens (human)
positive regulation of gene expression	Retinoic acid receptor gamma	Homo sapiens (human)
embryonic camera-type eye development	Retinoic acid receptor gamma	Homo sapiens (human)
regulation of myelination	Retinoic acid receptor gamma	Homo sapiens (human)
negative regulation of chondrocyte differentiation	Retinoic acid receptor gamma	Homo sapiens (human)
response to retinoic acid	Retinoic acid receptor gamma	Homo sapiens (human)
embryonic hindlimb morphogenesis	Retinoic acid receptor gamma	Homo sapiens (human)
multicellular organism growth	Retinoic acid receptor gamma	Homo sapiens (human)
positive regulation of apoptotic process	Retinoic acid receptor gamma	Homo sapiens (human)
positive regulation of programmed cell death	Retinoic acid receptor gamma	Homo sapiens (human)
regulation of myeloid cell differentiation	Retinoic acid receptor gamma	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Retinoic acid receptor gamma	Homo sapiens (human)
embryonic eye morphogenesis	Retinoic acid receptor gamma	Homo sapiens (human)
retinoic acid receptor signaling pathway	Retinoic acid receptor gamma	Homo sapiens (human)
canonical Wnt signaling pathway	Retinoic acid receptor gamma	Homo sapiens (human)
face development	Retinoic acid receptor gamma	Homo sapiens (human)
trachea cartilage development	Retinoic acid receptor gamma	Homo sapiens (human)
prostate gland epithelium morphogenesis	Retinoic acid receptor gamma	Homo sapiens (human)
Harderian gland development	Retinoic acid receptor gamma	Homo sapiens (human)
cellular response to retinoic acid	Retinoic acid receptor gamma	Homo sapiens (human)
stem cell proliferation	Retinoic acid receptor gamma	Homo sapiens (human)
cellular response to leukemia inhibitory factor	Retinoic acid receptor gamma	Homo sapiens (human)
negative regulation of stem cell proliferation	Retinoic acid receptor gamma	Homo sapiens (human)
cell differentiation	Retinoic acid receptor gamma	Homo sapiens (human)
hormone-mediated signaling pathway	Retinoic acid receptor gamma	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
mRNA regulatory element binding translation repressor activity	Retinoic acid receptor alpha	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Retinoic acid receptor alpha	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Retinoic acid receptor alpha	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Retinoic acid receptor alpha	Homo sapiens (human)
DNA-binding transcription repressor activity	Retinoic acid receptor alpha	Homo sapiens (human)
transcription coactivator binding	Retinoic acid receptor alpha	Homo sapiens (human)
retinoic acid binding	Retinoic acid receptor alpha	Homo sapiens (human)
chromatin binding	Retinoic acid receptor alpha	Homo sapiens (human)
DNA-binding transcription factor activity	Retinoic acid receptor alpha	Homo sapiens (human)
nuclear receptor activity	Retinoic acid receptor alpha	Homo sapiens (human)
signaling receptor binding	Retinoic acid receptor alpha	Homo sapiens (human)
protein binding	Retinoic acid receptor alpha	Homo sapiens (human)
zinc ion binding	Retinoic acid receptor alpha	Homo sapiens (human)
enzyme binding	Retinoic acid receptor alpha	Homo sapiens (human)
protein domain specific binding	Retinoic acid receptor alpha	Homo sapiens (human)
chromatin DNA binding	Retinoic acid receptor alpha	Homo sapiens (human)
histone deacetylase binding	Retinoic acid receptor alpha	Homo sapiens (human)
protein kinase B binding	Retinoic acid receptor alpha	Homo sapiens (human)
retinoic acid-responsive element binding	Retinoic acid receptor alpha	Homo sapiens (human)
mRNA 5'-UTR binding	Retinoic acid receptor alpha	Homo sapiens (human)
protein kinase A binding	Retinoic acid receptor alpha	Homo sapiens (human)
alpha-actinin binding	Retinoic acid receptor alpha	Homo sapiens (human)
heterocyclic compound binding	Retinoic acid receptor alpha	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Retinoic acid receptor alpha	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Retinoic acid receptor beta	Homo sapiens (human)
DNA binding	Retinoic acid receptor beta	Homo sapiens (human)
zinc ion binding	Retinoic acid receptor beta	Homo sapiens (human)
protein-containing complex binding	Retinoic acid receptor beta	Homo sapiens (human)
nuclear retinoid X receptor binding	Retinoic acid receptor beta	Homo sapiens (human)
heterocyclic compound binding	Retinoic acid receptor beta	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Retinoic acid receptor beta	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Retinoic acid receptor beta	Homo sapiens (human)
nuclear receptor activity	Retinoic acid receptor beta	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Retinoic acid receptor gamma	Homo sapiens (human)
DNA binding	Retinoic acid receptor gamma	Homo sapiens (human)
chromatin binding	Retinoic acid receptor gamma	Homo sapiens (human)
DNA-binding transcription factor activity	Retinoic acid receptor gamma	Homo sapiens (human)
protein binding	Retinoic acid receptor gamma	Homo sapiens (human)
zinc ion binding	Retinoic acid receptor gamma	Homo sapiens (human)
nuclear retinoid X receptor binding	Retinoic acid receptor gamma	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Retinoic acid receptor gamma	Homo sapiens (human)
nuclear receptor activity	Retinoic acid receptor gamma	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Retinoic acid receptor gamma	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Retinoic acid receptor alpha	Homo sapiens (human)
nucleoplasm	Retinoic acid receptor alpha	Homo sapiens (human)
transcription regulator complex	Retinoic acid receptor alpha	Homo sapiens (human)
nucleolus	Retinoic acid receptor alpha	Homo sapiens (human)
cytoplasm	Retinoic acid receptor alpha	Homo sapiens (human)
cytosol	Retinoic acid receptor alpha	Homo sapiens (human)
plasma membrane	Retinoic acid receptor alpha	Homo sapiens (human)
actin cytoskeleton	Retinoic acid receptor alpha	Homo sapiens (human)
dendrite	Retinoic acid receptor alpha	Homo sapiens (human)
perinuclear region of cytoplasm	Retinoic acid receptor alpha	Homo sapiens (human)
RNA polymerase II transcription regulator complex	Retinoic acid receptor alpha	Homo sapiens (human)
chromatin	Retinoic acid receptor alpha	Homo sapiens (human)
protein-containing complex	Retinoic acid receptor alpha	Homo sapiens (human)
nucleus	Retinoic acid receptor alpha	Homo sapiens (human)
nucleus	Retinoic acid receptor beta	Homo sapiens (human)
nucleoplasm	Retinoic acid receptor beta	Homo sapiens (human)
cytoplasm	Retinoic acid receptor beta	Homo sapiens (human)
chromatin	Retinoic acid receptor beta	Homo sapiens (human)
nucleus	Retinoic acid receptor beta	Homo sapiens (human)
nucleus	Retinoic acid receptor gamma	Homo sapiens (human)
nucleoplasm	Retinoic acid receptor gamma	Homo sapiens (human)
cytoplasm	Retinoic acid receptor gamma	Homo sapiens (human)
membrane	Retinoic acid receptor gamma	Homo sapiens (human)
chromatin	Retinoic acid receptor gamma	Homo sapiens (human)
transcription regulator complex	Retinoic acid receptor gamma	Homo sapiens (human)
nucleus	Retinoic acid receptor gamma	Homo sapiens (human)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346740	Human Retinoic acid receptor-alpha (1B. Retinoic acid receptors)	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
AID1346788	Human Retinoic acid receptor-gamma (1B. Retinoic acid receptors)	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
AID1346786	Human Retinoic acid receptor-beta (1B. Retinoic acid receptors)	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID392142	Activity at human RARgamma ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID396775	Activity at human RARalpha ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID396776	Activity at human RARalpha ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay relative to all-trans retinoic acid	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID392141	Activity at human RARbeta ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay relative to all-trans retinoic acid	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID392144	Activity at human RARgamma ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay relative to all-trans retinoic acid	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID396777	Activity at human RARbeta ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	63 (15.67)	18.2507
2000's	164 (40.80)	29.6817
2010's	105 (26.12)	24.3611
2020's	70 (17.41)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	131 (29.84%)	5.53%
Reviews	97 (22.10%)	6.00%
Case Studies	69 (15.72%)	4.05%
Observational	1 (0.23%)	0.25%
Other	141 (32.12%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (55)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac® (Tazarotene) Cream, 0.1%, in the Treatment of Acne Vulgaris [NCT02525822]	Phase 2	210 participants (Anticipated)	Interventional	2015-09-30	Not yet recruiting
A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled Study To Evaluate The Phototoxic Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers [NCT01115322]	Phase 1	38 participants (Actual)	Interventional	2010-04-01	Completed
A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Cumulative Irritation Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers [NCT01112787]	Phase 1	39 participants (Actual)	Interventional	2010-03-26	Completed
A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Photoallergic Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers [NCT01119651]	Phase 1	59 participants (Actual)	Interventional	2010-06-14	Completed
A Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks [NCT03292640]	Phase 3	547 participants (Actual)	Interventional	2017-07-06	Completed
Microneedling Versus Topical Tazarotene 0.1% Gel for the Treatment of Atrophic Post Acne Scarring - a Randomized Controlled Study [NCT03170596]		36 participants (Actual)	Interventional	2017-06-02	Completed
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris [NCT02886715]	Phase 3	1,110 participants (Actual)	Interventional	2016-09-21	Completed
Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna [NCT00707174]		90 participants (Actual)	Interventional	2005-03-31	Completed
Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. [NCT03263624]	Phase 4	30 participants (Anticipated)	Interventional	2017-10-01	Not yet recruiting
A Phase 1b Open Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis [NCT03058744]	Phase 1	94 participants (Actual)	Interventional	2015-04-30	Completed
Comparison Of The Efficacy Of Tazarotene 0.045% Versus Halobetasol Propionate 0.01% Lotion For the Treatment of Scalp Psoriasis [NCT06015152]		90 participants (Actual)	Interventional	2022-08-01	Completed
A Phase II Trial to Evaluate the Anti-psoriatic Efficacy and Tolerability of Tazarotene in a Gel Formulation in Patients With Mild to Moderate Nail Psoriasis - Parallel Group Comparison [NCT02235480]	Phase 2	66 participants (Actual)	Interventional	2014-02-28	Completed
[NCT02218034]	Phase 1	78 participants (Actual)	Interventional	2014-08-31	Completed
A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Contact Sensitization Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers [NCT01114841]	Phase 1	254 participants (Actual)	Interventional	2010-03-31	Completed
A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% (Taro Pharmaceuticals U.S.A., Inc.) to Duobrii® Lotion (Halobetasol Propionate and Tazarotene L [NCT05282771]	Early Phase 1	402 participants (Actual)	Interventional	2021-04-16	Completed
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis [NCT02886702]	Phase 3	855 participants (Actual)	Interventional	2016-09-19	Completed
A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris [NCT01016977]	Phase 4	40 participants (Actual)	Interventional	2009-10-31	Completed
Comparing the Efficacy of Topical Tazarotene Gel 0.1% Versus Microneedling in Atrophic Post Acne Scars [NCT05573425]	Phase 2/Phase 3	202 participants (Actual)	Interventional	2020-08-22	Completed
A Multiple-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to Tazorac® (Tazarotene Cream 0.1%) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris [NCT02411955]	Phase 1	1,077 participants (Actual)	Interventional	2014-06-30	Completed
A Demonstration of the Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion as Compared to 0.05% Clobetasol Propionate Cream in the Treatment of Psoriasis [NCT06042647]	Phase 4	10 participants (Actual)	Interventional	2023-07-13	Completed
A Demonstration of the Hair and Scalp Benefits of 0.045% Tazarotene/0.01% Halobetasol Lotion in Scalp Psoriasis [NCT05872256]	Phase 4	20 participants (Actual)	Interventional	2023-06-01	Completed
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Acne Vulgaris [NCT01017146]	Phase 3	744 participants (Actual)	Interventional	2009-10-31	Completed
Randomized Study Evaluating the Absorption and Systematic Pharmacokinetics of Topically Applied IDP-123 Lotion in Comparison With Tazorac Cream in Subjects With Moderate to Severe Acne Vulgaris Under Maximal Use Conditions [NCT02849873]	Phase 1	48 participants (Actual)	Interventional	2016-06-30	Completed
Single Center, Open-Label, Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails [NCT00648986]	Phase 4	20 participants (Actual)	Interventional	2005-08-31	Completed
A Randomized, Open-Label, Multiple Dose, Bioavailability Study of DFD-03 (Tazarotene Lotion, 0.1 % ) Dosed Twice Daily Compared to Once Daily Tazorac® (Tazarotene) Cream, 0.1% in Patients With Moderate Acne Vulgaris [NCT03599193]	Phase 2	58 participants (Actual)	Interventional	2017-10-04	Completed
A Single-Blind Study to Assess Benefits of a Controlled Daily Skin Care Regimen on Retinoid Intolerant Patients (Derm 570) [NCT00440024]		40 participants (Actual)	Interventional	2007-02-28	Completed
Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study [NCT00779896]	Phase 1/Phase 2	15 participants (Anticipated)	Interventional	2008-10-31	Recruiting
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Acne Vulgaris [NCT01017120]	Phase 3	742 participants (Actual)	Interventional	2009-10-01	Completed
Investigator-Initiated, Open Label Trial of a Combination of Halobetasol Propionate 0.01% Andtazarotene 0.045% Lotion (Duobrii®) for Plaque Type Psoriasis of the Hands and/or Feet [NCT04720105]	Phase 4	22 participants (Actual)	Interventional	2020-11-19	Completed
A Multi-center, Randomized, Double-blind, Vehicle-Controlled, Phase 2 Study of the Safety and Efficacy of Benzoyl Peroxide/Clindamycin Gel and Tazarotene Cream When Used in Combination in the Treatment of Acne Vulgaris [NCT00713609]	Phase 2	591 participants (Actual)	Interventional	2008-06-30	Completed
Regimen of Tazorac .1% Gel & Minocycline Cap in Tx of Individuals w/Acne Vulgaris: Effects of Maintenance Therapy on Duration of Improvement of Tazorac .1% Gel Used in Conjunction w/Placebo Cap Compared w/Minocycline Cap Used in Conjunction w/Either Tazor [NCT00145106]	Phase 4	189 participants	Interventional	2002-03-31	Completed
A Single-Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris [NCT01019603]	Phase 1	30 participants (Actual)	Interventional	2009-10-12	Completed
Comparison of Safety and Efficacy of Tazarotene 0.1% Plus Clindamycin 1% Gel vs. Adapalene 0.1% Plus Clindamycin 1% Gel in the Treatment of Facial Acne Vulgaris: A Randomized Controlled Trial [NCT02721173]	Phase 4	60 participants (Actual)	Interventional	2016-04-30	Completed
A Double-Blind,Randomized,Parallel-Group,Vehicle-Controlled,Multi-Center Study Comparing a Generic Tazarotene Cream, 0.05% to RLD Tazorac® Cream, 0.05% and Both Treatments to a Vehicle in the Treatment of Plaque Psoriasis [NCT02160665]	Phase 3	866 participants (Actual)	Interventional	2014-05-31	Completed
A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac® (Tazarotene) Cream, in the Treatment of Acne Vulgaris [NCT02938494]	Phase 2	210 participants (Actual)	Interventional	2015-11-30	Completed
A Double-Blind,Randomized,Parallel-Group,Vehicle-Controlled,MulticenterStudy ComparingaGenericTazaroteneCream,0.1%toReference Listed Drug Tazorac® Cream, 0.1% and Both Active Treatments to Vehicle Control in the Treatment of Acne Vulgaris [NCT02160678]	Phase 3	1,741 participants (Actual)	Interventional	2014-05-31	Completed
A Randomized, Double-Blind, Active-Controlled Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® (Tazarotene) Cream, 0.1% in the Topical Treatment of Acne Vulgaris for 12 Weeks [NCT03341910]	Phase 2	155 participants (Actual)	Interventional	2017-08-21	Completed
[NCT00834210]	Phase 4	171 participants (Actual)	Interventional	2008-12-31	Completed
Photodynamic Therapy With Levulan® Topical Solution And Blue Light +/- Topical Retinoid Pre-Treatment In The Treatment Of Dorsal Hand/Forearm Actinic Keratoses [NCT01053000]		10 participants (Actual)	Interventional	2010-01-31	Completed
Four-arm Study to Evaluate Urea 40% Cream, Fluocinonide 0.05% Cream, Tazarotene 0.1% Cream, and an Emollient Cream for the Treatment of Hand-foot Skin Reaction Related to the Use of Multi-targeted Tyrosine Kinase Inhibitor Sorafenib. [NCT00667589]	Phase 2	6 participants (Actual)	Interventional	2008-06-30	Terminated(stopped due to Study was halted due to poor subject accrual.)
A Phase II Randomized, Double-Blind, Vehicle-Controlled, Crossover Clinical Trial of Tazarotene 0.1% and Vehicle Cream Each Applied Once-Daily for 12 or 24 Months in Subjects With Basal Cell Nevus Syndrome [NCT00783965]	Phase 2	34 participants (Actual)	Interventional	2004-07-31	Completed
A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome [NCT00489086]	Phase 2	36 participants (Actual)	Interventional	2004-07-31	Completed
[NCT00829049]	Phase 4	165 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to Study enrollment was terminated due to company decision before the target enrollment of 220 patients was reached.)
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris [NCT01616654]	Phase 2	304 participants (Actual)	Interventional	2012-06-20	Completed
Efficacy of Excimer Laser Combined With Either Topical Tazarotene or Topical Betamethasone Valerate Versus Excimer Laser Alone in Treatment of Localized Chronic Plaque Psoriasis; Clinical and Dermoscopic Study [NCT05555797]	Phase 4	30 participants (Anticipated)	Interventional	2022-10-30	Not yet recruiting
Open Clinical Study, Comparing Non-inferiority for Efficacy of the Drug Tazarotene 0.1% Versus the Comparator Drug Calcipotriol 0.005% in the Treatment of Chronic Plaque Psoriasis [NCT01279629]		50 participants (Anticipated)	Observational	2011-02-28	Suspended
A Multicenter, Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled Study to Evaluate the Safety and Therapeutic Equivalence of a Generic Tazarotene Foam 0.1%(Actavis) and the Reference Listed Fabior™(Tazarotene Foam, 0.1%) (Stiefel Laboratories, [NCT02267746]	Phase 3	893 participants (Actual)	Interventional	2014-06-30	Completed
Efficacy of Tazarotene Versus Topical 5-Fluorouracil, and Imiquimod in The Treatment of Verruca Plana [NCT05314127]	Phase 2	80 participants (Anticipated)	Interventional	2022-04-15	Recruiting
A Prospective, Single-center, Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of Tazarotene 0.045% Lotion (Arazlo) for Treating Postinflammatory Erythema and Postinflammatory Hyperpigmentation in Subjects With Acne [NCT05704114]	Phase 4	20 participants (Actual)	Interventional	2021-02-01	Completed
A Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks [NCT03290027]	Phase 3	550 participants (Actual)	Interventional	2017-07-31	Completed
A Phase 2, Multicenter, Double Blinded, Randomized, Vehicle Controlled Study to Compare the Safety and Efficacy of IDP-118 Lotion With Tazorac (Tazarotene) Cream, 0.05% in the Treatment of Plaque Psoriasis [NCT02785159]	Phase 2	152 participants (Actual)	Interventional	2016-02-29	Completed
A Comparison of Treatment of Psoriasis With Acitretin or Tazarotene Gel 0.1% and Active or Sham Treatments With the 308 nm Excimer Laser [NCT01094717]		13 participants (Actual)	Interventional	2010-01-31	Terminated(stopped due to lack of efficacy and lack of funding)
A Phase II Randomized Double-Blind Trial of Topical Tazarotene 0.1% Gel Versus Placebo Gel for the Prevention of Regorafenib-Induced Hand-Foot-Skin Reaction [NCT04071756]	Phase 2	8 participants (Actual)	Interventional	2019-12-30	Terminated(stopped due to Difficulty with patient recruitment)
A Comparison of Differin® Gel, 0.1% vs. Tazorac® Cream, 0.1% vs. Differin® Gel, 0.1% 6-week Treatment Switched to Tazorac® Cream, 0.1% 6-week Treatment in Patients With Acne Vulgaris [NCT00469755]	Phase 4	302 participants (Actual)	Interventional	2006-02-28	Completed
Efficacy and Safety of Duobrii in the Management of Acne Keloidalis Nuchae (AKN) [NCT05608499]	Phase 3	30 participants (Anticipated)	Interventional	2022-10-26	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00489086 (5) [back to overview]	Estimated Duration of Complete Response
NCT00489086 (5) [back to overview]	Complete Response Rate
NCT00489086 (5) [back to overview]	Overall Response at Treated Lesions
NCT00489086 (5) [back to overview]	Time to Lesion Clearance
NCT00489086 (5) [back to overview]	Time to Progression
NCT00667589 (2) [back to overview]	Change in Skindex-16 Total Score Between Baseline and 2 Weeks
NCT00667589 (2) [back to overview]	Change in Skindex-16 Total Score Between Baseline and 8 Weeks
NCT00707174 (1) [back to overview]	The Absence of Lentigo Maligna (LM) at the Time of Staged Excisions in Participants
NCT00713609 (4) [back to overview]	Percent Change From Baseline to Week 12 in Each of 3 Lesion Counts (Total, Inflammatory, and Non-inflammatory)
NCT00713609 (4) [back to overview]	Absolute Change in Lesion Counts (Total, Inflammatory, and Non-inflammatory) From Baseline to Week 12
NCT00713609 (4) [back to overview]	Proportion of Participants With a Minimum 2-grade Improvement in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12
NCT00713609 (4) [back to overview]	Proportion of Participants With an ISGA Score of 0 or 1 at Week 12
NCT00783965 (2) [back to overview]	Number of Participants With Reduction in the Observed Numbers of Basal Cell Carcinomas ≥ 9 mm² in Diameter
NCT00783965 (2) [back to overview]	Parameters of Safety: Number of Participants With Adverse Events According to NCI CTCAE v3.0
NCT00829049 (4) [back to overview]	Percentage of Patients With >= 2 Grade Improvement in the Overall Disease Severity Score at Week 12
NCT00829049 (4) [back to overview]	Median Percent Change From Baseline in Inflammatory Lesion Counts (Papules/Pustules, Nodules) at Week 16
NCT00829049 (4) [back to overview]	Median Percent Change From Baseline in the Non-Inflammatory Lesion Counts (Open and Closed Comedones) at Week 12
NCT00829049 (4) [back to overview]	Percentage of Patients With >= 1 Grade Improvement in the Investigator Global Assessment at Week 16
NCT00834210 (4) [back to overview]	Change From Baseline in Non-Inflammatory Lesion Counts (Open and Closed Comedones) at Week 12
NCT00834210 (4) [back to overview]	Change From Baseline in Inflammatory Lesion Counts (Papules,Pustules, and Nodules) at Week 12
NCT00834210 (4) [back to overview]	Change From Baseline in Investigator Global Assessment at Week 12
NCT00834210 (4) [back to overview]	Change From Baseline in Overall Disease Severity at Week 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline in Skin Overall Comfort at Weeks 1, 2, 4, 8, and 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline in Total Lesion Count at Weeks 1, 2, 4, 8, and 12
NCT01016977 (15) [back to overview]	Overall Satisfaction With Study Product at Week 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline for the Emotional Score of the Participant-completed Skindex-29 Quality of Life Questionnaire at Week 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline for the Functional Score of the Participant-completed Skindex-29 Quality of Life Questionnaire at Week 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline for the Global Score of the Participant-completed Skindex-29 Quality of Life Questionnaire at Week 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline for the Symptomatic Score of the Participant-completed Skindex-29 Quality of Life Questionnaire at Week 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline in Burning/Stinging at Weeks 1, 2, 4, 8, and 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline in Dryness at Weeks 1, 2, 4, 8, and 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline in Erythema at Weeks 1, 2, 4, 8, and 12
NCT01016977 (15) [back to overview]	Number of Participants With at Least a Two-grade Improvement in ISGA Score From Baseline to Week 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline in Itching at Weeks 1, 2, 4, 8, and 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline in Oiliness at Weeks 1, 2, 4, 8, and 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline in Peeling at Weeks 1, 2, 4, 8, and 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline in Inflammatory and Non-inflammatory Lesion Counts at Weeks 1, 2, 4, 8, and 12
NCT01017120 (22) [back to overview]	Absolute Change in Papule Count From Baseline at Weeks 2, 4, 8, and 12
NCT01017120 (22) [back to overview]	Absolute Change in Pustule Count From Baseline at Weeks 2, 4, 8, and 12
NCT01017120 (22) [back to overview]	Change in Children's Dermatology Life Quality Index (CDLQI) From Baseline at Week 2, 4, 8 and 12 in Participant's With 16 Years Old or Younger
NCT01017120 (22) [back to overview]	Change in Dermatology Life Quality Index (DLQI) Score From Baseline at Weeks 2, 4, 8, and 12 in Participants 17 Years of Age or Older
NCT01017120 (22) [back to overview]	Number of Participants With an ISGA Score of 0 or 1 at Weeks 2, 4, and 8
NCT01017120 (22) [back to overview]	Percent Change in LC From Baseline at Weeks 2, 4, 8, and 12
NCT01017120 (22) [back to overview]	Number of Participants With the Indicated Local Tolerability Assessment for Peeling as Evaluated by the Investigator
NCT01017120 (22) [back to overview]	Number of Participants With the Indicated Local Tolerability Assessment for Erythema as Evaluated by the Investigator
NCT01017120 (22) [back to overview]	Number of Participants With the Indicated Local Tolerability Assessment for Drying as Evaluated by the Investigator
NCT01017120 (22) [back to overview]	Number of Participants With a 2-G Improvement in ISGA Score and an ISGA Score of 0 or 1 at Weeks 2, 4, 8, and 12
NCT01017120 (22) [back to overview]	Number of Participants With a Subject's Global Assessment (SGA) Score of 0 or 1 at Weeks 2, 4, 8, and 12
NCT01017120 (22) [back to overview]	Number of Participants With a Minimum 2 G Improvement in ISGA Score at Weeks 2, 4, and 8
NCT01017120 (22) [back to overview]	Number of Participants With the Indicated Local Tolerability Assessment for Burning/Stinging as Evaluated by the Participants
NCT01017120 (22) [back to overview]	Number of Participants With the Indicated Local Tolerability Assessment for Itching as Evaluated by the Participants
NCT01017120 (22) [back to overview]	Number of Participants With a Minimum 2-grade (G) Improvement in the Investigator Static Global Assessment (ISGA) Score From Baseline at Week 12
NCT01017120 (22) [back to overview]	Number of Participants With an ISGA Score of 0 or 1 at Week 12
NCT01017120 (22) [back to overview]	Time to a 50 Percent Reduction in Total Lesion Counts (TLC)
NCT01017120 (22) [back to overview]	Absolute Change From Baseline in LC at Weeks 2, 4, and 8
NCT01017120 (22) [back to overview]	Absolute Change in Closed Comedone Count From Baseline at Weeks 2, 4, 8, and 12
NCT01017120 (22) [back to overview]	Absolute Change in Lesion Counts (LCs) From Baseline to Week 12
NCT01017120 (22) [back to overview]	Absolute Change in Nodule Count From Baseline at Weeks 2, 4, 8, and 12
NCT01017120 (22) [back to overview]	Absolute Change in Open Comedone Count From Baseline at Weeks 2, 4, 8, and 12
NCT01017146 (16) [back to overview]	Number of Participants With an ISGA Score of 0 or 1 at Week 12
NCT01017146 (16) [back to overview]	Time to a 50 Percent Reduction in Total Lesion Counts (TLC)
NCT01017146 (16) [back to overview]	Absolute Change in Lesion Counts (LCs) From Baseline to Week 12
NCT01017146 (16) [back to overview]	Change in Children's Dermatology Life Quality Index (CDLQI) From Baseline at Week 2, 4, 8 and 12 in Participant's With 16 Years Old or Younger
NCT01017146 (16) [back to overview]	Change in Dermatology Life Quality Index (DLQI) Score From Baseline at Weeks 2, 4, 8, and 12 in Participants 17 Years of Age or Older
NCT01017146 (16) [back to overview]	Number of Participants With a Minimum 2-grade Improvement in ISGA Score at Weeks 2, 4, and 8
NCT01017146 (16) [back to overview]	Number of Participants With a Subject's Global Assessment (SGA) Score of 0 or 1 at Weeks 2, 4, 8, and 12
NCT01017146 (16) [back to overview]	Number of Participants With an ISGA Score of 0 or 1 at Weeks 2, 4, and 8
NCT01017146 (16) [back to overview]	Number of Participants With the Indicated Local Tolerability Assessment for Burning/Stinging as Evaluated by the Participants
NCT01017146 (16) [back to overview]	Number of Participants With the Indicated Local Tolerability Assessment for Drying as Evaluated by the Investigator
NCT01017146 (16) [back to overview]	Number of Participants With the Indicated Local Tolerability Assessment for Erythema as Evaluated by the Investigator
NCT01017146 (16) [back to overview]	Number of Participants With the Indicated Local Tolerability Assessment for Itching as Evaluated by the Participants
NCT01017146 (16) [back to overview]	Number of Participants With the Indicated Local Tolerability Assessment for Peeling as Evaluated by the Investigator
NCT01017146 (16) [back to overview]	Percent Change in LC From Baseline at Weeks 2, 4, 8, and 12
NCT01017146 (16) [back to overview]	Absolute Change From Baseline in LC at Weeks 2, 4, and 8
NCT01017146 (16) [back to overview]	Number of Participants With a Minimum 2-grade (G) Improvement in the Investigator Static Global Assessment (ISGA) Score From Baseline at Week 12
NCT01053000 (1) [back to overview]	Change in Lesion Counts in 25 cm2 Target Area Relative to Baseline.
NCT01094717 (3) [back to overview]	Number of Patients That Achieved an Average Lesion Assessment Score of 0 or 1 at Week 12.
NCT01094717 (3) [back to overview]	Change in the NPF Psoriasis Score of Plaques
NCT01094717 (3) [back to overview]	Number of Participants With Adverse Events
NCT01616654 (6) [back to overview]	Percentage Change From Baseline in Total Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)
NCT01616654 (6) [back to overview]	Absolute Change From Baseline in Total Lesion Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)
NCT01616654 (6) [back to overview]	Percentage Change From Baseline in Inflammatory and Non-inflammatory Lesion Count up to Week 12 Using Last Observation Carried Forward (LOCF)
NCT01616654 (6) [back to overview]	Absolute Change From Baseline in Inflammatory and Non-inflammatory Lesion Count up to Week 12 Using Last Observation Carried Forward (LOCF)
NCT01616654 (6) [back to overview]	Percentage of Participants With Success Rate 2 (SR2)
NCT01616654 (6) [back to overview]	Percentage of Participants With Success Rate 1 (SR1)
NCT02267746 (2) [back to overview]	Percent Change in the Non-inflammatory (Open and Closed Comedones) Lesion Counts
NCT02267746 (2) [back to overview]	Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts
NCT02785159 (1) [back to overview]	Percent of Subjects With Treatment Success, Defined by at Least a 2 Grade Improvement From Baseline in the Investigator Global Assessment (IGA) Score Equating to Clear or Almost Clear.
NCT02886702 (3) [back to overview]	Treatment Success Assessed by IGA
NCT02886702 (3) [back to overview]	Target Site Plaque Elevation, Scaling and Erythema Scores of Less Than or Equal to 1 on the PASI
NCT02886702 (3) [back to overview]	Disease Severity None or Minimal on IGA
NCT02886715 (3) [back to overview]	Clinical Response of Success
NCT02886715 (3) [back to overview]	Change in Non-inflammatory Lesion Counts
NCT02886715 (3) [back to overview]	Change in Inflammatory Lesion Counts
NCT02938494 (3) [back to overview]	Percentage of Participants With Treatment Success at Week 12
NCT02938494 (3) [back to overview]	Absolute Change From Baseline in Mean Inflammatory Lesion Count to Week 12
NCT02938494 (3) [back to overview]	Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12
NCT03290027 (3) [back to overview]	Proportion of Subjects With Treatment Success Based on IGA Score
NCT03290027 (3) [back to overview]	Absolute Change in the Inflammatory Lesion Counts on the Face
NCT03290027 (3) [back to overview]	Absolute Change in the Non-inflammatory Lesion Counts on the Face
NCT03292640 (3) [back to overview]	Absolute Change in the Non-inflammatory Lesion Counts on the Face
NCT03292640 (3) [back to overview]	"Proportion of Subjects With a Clinical Response of Success at Week 12 for Lesions on the Face Based on IGA."
NCT03292640 (3) [back to overview]	Absolute Change in the Inflammatory Lesion Counts on the Face
NCT03341910 (1) [back to overview]	Adverse Event Occurences in DFD-03 Lotion Versus Tazorac Cream Groups
NCT03599193 (4) [back to overview]	Number of Subjects With Treatment Emergent Adverse Events (TEAE)
NCT03599193 (4) [back to overview]	Area Under the Curve (AUC0-24) at Steady State
NCT03599193 (4) [back to overview]	Maximum Plasma Concentration (Cmax)
NCT03599193 (4) [back to overview]	Time to Maximum Concentration (Tmax) of Tazarotenic Acid
NCT04071756 (4) [back to overview]	All Grade Hand-Foot Skin Reaction (HFSR) Rate
NCT04071756 (4) [back to overview]	Change in HFS-14 Score From Baseline to Day 56
NCT04071756 (4) [back to overview]	Change in Perceived Stress Scale (PSS) From Baseline to Day 56
NCT04071756 (4) [back to overview]	Grade 2 or Higher Hand-Foot Skin Reaction (HFSR) Rate
NCT04720105 (3) [back to overview]	Palmoplantar Physician Global Assessment (ppPGA)
NCT04720105 (3) [back to overview]	Numerical Rating Scale (NRS)
NCT04720105 (3) [back to overview]	Dermatology Quality of Life Index (DLQI)

Estimated Duration of Complete Response

(NCT00489086)
Timeframe: 36 months

Intervention	Participants (Count of Participants)
Tazarotene Cream	NA

Intervention	units on a scale (Mean)
Fluocinonide 0.05% Cream	36
Tazarotene 0.1% Cream	-9.5
Urea 40% Cream	1

Intervention	Percent change (Mean)
	ILC, n=101, 103, 105, 105, 104, 52	NILC, n=101, 103, 105, 105, 104, 52	TLC, n=101, 103, 105, 105, 104, 52
Benzoyl Peroxide Gel + Tazarotene	-62.4	-60.6	-62.0
Benzoyl Peroxide/Clindamycin + Tazarotene	-58.3	-58.0	-59.1
Benzoyl Peroxide/Clindamycin + Vehicle Cream	-62.4	-39.2	-47.9
Clindamycin Gel + Tazarotene	-65.7	-61.2	-63.4
Vehicle Gel + Tazarotene	-49.0	-53.1	-51.8
Vehicle Gel + Vehicle Cream	-33.5	-29.5	-31.5

Intervention	Number of lesions (Mean)
	Baseline	Week 12
Dapsone Gel 5% and Tazarotene Cream 0.1%	46.42	-26.73
Tazarotene Cream 0.1%	46.48	-21.74

Intervention	units on a scale (Mean)
	Week 1, n=19, 17	Week 2, n=20, 19	Week 4, n=20, 20	Week 8, n=20, 20	Week 12, n=20, 20
Tazorac Cream/Acanya Gel	-0.29	0.05	-0.10	0.10	0.60
Tazorac Cream/Duac Gel	-0.37	0.25	0.05	0.30	0.45

Intervention	units on a scale (Mean)
	Morning	Evening
Tazorac Cream/Acanya Gel	1.75	1.70
Tazorac Cream/Duac Gel	1.76	1.59

Intervention	lesions (Mean)
	W1, Inflammatory lesions, n=19, 17	W2, Inflammatory lesions, n=20, 19	W4, Inflammatory lesions, n=20, 20	W8, Inflammatory lesions, n=20, 20	W12, Inflammatory lesions, n=20, 20	W1, Non-inflammatory lesions, n=19, 17	W2, Non-inflammatory lesions, n=20, 19	W4, Non-inflammatory lesions, n=20, 20	W8, Non-inflammatory lesions, n=20, 20	W12, Non-inflammatory lesions, n=20, 20
Tazorac Cream/Acanya Gel	-5.9	-8.1	-9.6	-16.3	-13.4	-7.6	-15.1	-26.6	-33.1	-37.8
Tazorac Cream/Duac Gel	-6.6	-8.8	-13.0	-14.9	-18.0	-3.2	-17.9	-23.6	-28.9	-32.6

Intervention	papule count (Mean)
	Week 2	Week 4	Week 8	Week 12
Tazarotene Foam	-4.3	-8.3	-12.0	-13.5
Vehicle Foam	-4.3	-7.8	-10.4	-11.5

Intervention	scores on a scale (Mean)
	Week 2, n=153, 163	Week 4, n=143, 158	Week 8, n=137, 158	Week 12, n=137, 153
Tazarotene Foam	1.3	-0.9	-1.6	-1.6
Vehicle Foam	-1.5	-1.9	-1.9	-2.0

Intervention	scores on a scale (Mean)
	Week 2, n=175, 178	Week 4, n=170, 184	Week 8, n=163, 176	Week 12, n=162, 176
Tazarotene Foam	-1.3	-2.4	-2.9	-3.7
Vehicle Foam	-1.9	-2.7	-3.1	-3.2

Intervention	percentage change (Mean)
	ILs, Week 2	ILs, Week 4	ILs, Week 8	ILs, Week 12	NILs, Week 2	NILs, Week 4	NILs, Week 8	NILs, Week 12	TLs, Week 2	TLs, Week 4	TLs, Week 8	TLs, Week 12
Tazarotene Foam	-18.2	-32.9	-48.1	-54.5	-23.7	-39.2	-50.6	-56.7	-21.6	-36.8	-49.7	-56.0
Vehicle Foam	-17.4	-31.4	-41.0	-45.3	-17.3	-27.3	-36.6	-41.2	-17.1	-28.9	-38.4	-42.6

Intervention	participants (Number)
	Baseline, G0	Baseline, G1	Baseline, G2	Baseline, G3	Baseline, G4	Baseline, Missing G	MDT, G0	MDT, G1	MDT, G2	MDT, G3	MDT, G4	MDT, Missing G	Week 12, G0	Week 12, G1	Week 12, G2	Week 12, G3	Week 12, G4	Week 12, Missing G
Tazarotene Foam	342	22	7	2	0	0	108	152	69	28	5	11	251	48	7	1	0	66
Vehicle Foam	339	18	6	6	0	0	255	85	18	3	0	8	313	17	1	0	0	38

Intervention	lesion counts (Mean)
	ILs	NILs	TLs
Tazarotene Foam	-17.8	-25.6	-43.4
Vehicle Foam	-14.7	-18.2	-32.9

Intervention	scores on a scale (Mean)
	Week 2, n=162,179	Week 4, n=153, 180	Week 8, n=148, 171	Week 12, n=146, 169
Tazarotene Foam	1.1	-0.6	-1.2	-1.7
Vehicle Foam	-1.4	-1.4	-1.9	-2.0

Intervention	Scores on a scale (Mean)
	Week 2, n=171,165	Week 4, n=166, 167	Week 8, n=160, 155	Week 12, n=154, 155
Tazarotene Foam	-0.1	-1.9	-2.9	-3.6
Vehicle Foam	-2.1	-2.5	-2.7	-3.1

Intervention	participants (Number)
Acitretin and Excimer	1
Acitretin and Sham Excimer Laser	0
Tazarotene and Excimer	0
Tazarotene and Sham Excimer Laser	0

Intervention	percentage change (Mean)
Acitretin and Excimer	-64.0
Acitretin and Sham (Placebo) Excimer	-52.1
Tazarotene Gel and Excimer Laser	-32.7
Tazarotene Gel and Sham (Placebo) Excimer	-26.9

Intervention	Participants (Count of Participants)
	any adverse event	severe adverse events
Acitretin and Active Excimer Laser	2	0
Acitretin and Sham Excimer Laser	2	0
Tazarotene and Active Excimer Laser	4	0
Tazarotene and Sham Excimer Laser	4	0

Intervention	percentage change (Mean)
CD5789 25 mcg/g Cream	-47.59
CD5789 50 mcg/g Cream	-49.87
CD5789 100 mcg/g Cream	-50.72
Tazarotene 0.1% Gel	-55.07
CD5789 Vehicle Cream	-40.48

Intervention	lesion count (Least Squares Mean)
CD5789 25 mcg/g Cream	-53.61
CD5789 50 mcg/g Cream	-54.75
CD5789 100 mcg/g Cream	-54.99
Tazarotene 0.1% Gel	-59.84
Vehicle Cream	-46.87

Intervention	percentage change (Mean)
	Inflammatory lesion count	Non-inflammatory lesion count
CD5789 100 mcg/g Cream	-51.93	-49.57
CD5789 25 mcg/g Cream	-49.16	-46.34
CD5789 50 mcg/g Cream	-53.14	-45.26
CD5789 Vehicle Cream	-41.70	-38.20
Tazarotene 0.1% Gel	-53.09	-55.88

tazarotene

Description

Cross-References

Synonyms (112)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (5)

Protein Targets (40)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (229)

Molecular Functions (75)

Ceullar Components (39)

Bioassays (88)

Research

Studies (402)

Market Indicators

Research Demand Index: 56.41

Study Types

Clinical Trials (55)

Trial Overview

Trial Outcomes

Estimated Duration of Complete Response

Complete Response Rate

Overall Response at Treated Lesions

Time to Lesion Clearance

Time to Progression

Change in Skindex-16 Total Score Between Baseline and 2 Weeks

Change in Skindex-16 Total Score Between Baseline and 8 Weeks

The Absence of Lentigo Maligna (LM) at the Time of Staged Excisions in Participants

Percent Change From Baseline to Week 12 in Each of 3 Lesion Counts (Total, Inflammatory, and Non-inflammatory)

Absolute Change in Lesion Counts (Total, Inflammatory, and Non-inflammatory) From Baseline to Week 12

Proportion of Participants With a Minimum 2-grade Improvement in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12

Proportion of Participants With an ISGA Score of 0 or 1 at Week 12

Number of Participants With Reduction in the Observed Numbers of Basal Cell Carcinomas ≥ 9 mm² in Diameter

Parameters of Safety: Number of Participants With Adverse Events According to NCI CTCAE v3.0

Percentage of Patients With >= 2 Grade Improvement in the Overall Disease Severity Score at Week 12

Median Percent Change From Baseline in Inflammatory Lesion Counts (Papules/Pustules, Nodules) at Week 16

Median Percent Change From Baseline in the Non-Inflammatory Lesion Counts (Open and Closed Comedones) at Week 12

Percentage of Patients With >= 1 Grade Improvement in the Investigator Global Assessment at Week 16

Change From Baseline in Non-Inflammatory Lesion Counts (Open and Closed Comedones) at Week 12

Change From Baseline in Inflammatory Lesion Counts (Papules,Pustules, and Nodules) at Week 12

Change From Baseline in Investigator Global Assessment at Week 12

Change From Baseline in Overall Disease Severity at Week 12

Mean Change From Baseline in Skin Overall Comfort at Weeks 1, 2, 4, 8, and 12

Mean Change From Baseline in Total Lesion Count at Weeks 1, 2, 4, 8, and 12

Overall Satisfaction With Study Product at Week 12

Mean Change From Baseline for the Emotional Score of the Participant-completed Skindex-29 Quality of Life Questionnaire at Week 12

Mean Change From Baseline for the Functional Score of the Participant-completed Skindex-29 Quality of Life Questionnaire at Week 12

Mean Change From Baseline for the Global Score of the Participant-completed Skindex-29 Quality of Life Questionnaire at Week 12

Mean Change From Baseline for the Symptomatic Score of the Participant-completed Skindex-29 Quality of Life Questionnaire at Week 12

Mean Change From Baseline in Burning/Stinging at Weeks 1, 2, 4, 8, and 12

Mean Change From Baseline in Dryness at Weeks 1, 2, 4, 8, and 12

Mean Change From Baseline in Erythema at Weeks 1, 2, 4, 8, and 12

Number of Participants With at Least a Two-grade Improvement in ISGA Score From Baseline to Week 12

Mean Change From Baseline in Itching at Weeks 1, 2, 4, 8, and 12

Mean Change From Baseline in Oiliness at Weeks 1, 2, 4, 8, and 12

Mean Change From Baseline in Peeling at Weeks 1, 2, 4, 8, and 12

Mean Change From Baseline in Inflammatory and Non-inflammatory Lesion Counts at Weeks 1, 2, 4, 8, and 12

Absolute Change in Papule Count From Baseline at Weeks 2, 4, 8, and 12

Absolute Change in Pustule Count From Baseline at Weeks 2, 4, 8, and 12

Change in Children's Dermatology Life Quality Index (CDLQI) From Baseline at Week 2, 4, 8 and 12 in Participant's With 16 Years Old or Younger

Change in Dermatology Life Quality Index (DLQI) Score From Baseline at Weeks 2, 4, 8, and 12 in Participants 17 Years of Age or Older

Number of Participants With an ISGA Score of 0 or 1 at Weeks 2, 4, and 8

Percent Change in LC From Baseline at Weeks 2, 4, 8, and 12

Number of Participants With the Indicated Local Tolerability Assessment for Peeling as Evaluated by the Investigator

Number of Participants With the Indicated Local Tolerability Assessment for Erythema as Evaluated by the Investigator

Number of Participants With the Indicated Local Tolerability Assessment for Drying as Evaluated by the Investigator

Number of Participants With a 2-G Improvement in ISGA Score and an ISGA Score of 0 or 1 at Weeks 2, 4, 8, and 12

Number of Participants With a Subject's Global Assessment (SGA) Score of 0 or 1 at Weeks 2, 4, 8, and 12

Intervention	lesion count (Mean)
	Inflammatory Lesions	Non-inflammatory Lesions
CD5789 100 mcg/g Cream	-19.32	-23.70
CD5789 25 mcg/g Cream	-19.67	-24.30
CD5789 50 mcg/g Cream	-21.11	-18.69
CD5789 Vehicle Cream	-17.74	-17.70
Tazarotene 0.1% Gel	-21.03	-28.26

Intervention	percentage of participants (Number)
CD5789 25 mcg/g Cream	13.11
CD5789 50 mcg/g Cream	14.75
CD5789 100 mcg/g Cream	16.67
Tazarotene 0.1% Gel	21.31
Vehicle Cream	8.20

Intervention	percentage of participants (Number)
CD5789 25 mcg/g Cream	29.51
CD5789 50 mcg/g Cream	32.79
CD5789 100 mcg/g Cream	26.67
Tazarotene 0.1% Gel	32.79
CD5789 Vehicle Cream	16.39

Intervention	percentage of participants (Number)
IDP-118 Lotion	31.66
Tazorac Cream	13.77
IDP 118 Vehicle Lotion	15.90
IDP-118 Vehicle Cream	7.96

Intervention	Participants (Count of Participants)
IDP-123 Lotion	13
Tazorac Cream	12
Vehicle Lotion and Vehicle Cream Combined	7

Intervention	lesions (Mean)
IDP-123 Lotion	-18.1
Tazorac Cream	-16.8
Vehicle Lotion and Vehicle Cream Combined	-14.0

Intervention	Lesions (Mean)
	Baseline	Week 12
DFD-03 Lotion (0.1% Tazarotene)	44.8	24.3
DFD-03 Vehicle (0% Tazarotene)	44.4	29.7

Intervention	Adverse Events (Number)
DFD-03 Lotion, 0.1%	73
Tazorac Cream, 0.1%	81
DFD-03 Vehicle Lotion	14
Tazorac Vehicle Cream	15

Intervention	percentage of participants (Number)
Topical Tazarotene 0.1% Gel Plus BPS	100
Placebo Gel Plus BPS	100

Intervention	percent of participants (Number)
Topical Tazarotene 0.1% Gel Plus BPS	20
Placebo Gel Plus BPS	33.33